Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells

Signals transmitted by binding of Fas ligand (FasL) to the Fas receptor (CD95/Apo-1) have pleiotropic effects on cellular function that present opportunities for therapeutic applications. For example, depending on the circumstances, overexpression of FasL can enhance, prevent, or reverse growth of s...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 112(2004), 1 vom: 16. Juli, Seite 54-65
1. Verfasser: Modiano, Jaime F (VerfasserIn)
Weitere Verfasser: Sun, Juan, Lang, Julie, Vacano, Guido, Patterson, David, Chan, Daniel, Franzusoff, Alex, Gianani, Roberto, Meech, Sandra J, Duke, Richard, Bellgrau, Donald
Format: Aufsatz
Sprache:English
Veröffentlicht: 2004
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Fas Ligand Protein Fasl protein, mouse Membrane Glycoproteins
LEADER 01000naa a22002652 4500
001 NLM148943209
003 DE-627
005 20231223050657.0
007 tu
008 231223s2004 xx ||||| 00| ||eng c
028 5 2 |a pubmed24n0497.xml 
035 |a (DE-627)NLM148943209 
035 |a (NLM)15207782 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Modiano, Jaime F  |e verfasserin  |4 aut 
245 1 0 |a Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells 
264 1 |c 2004 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 19.08.2004 
500 |a Date Revised 14.11.2007 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Signals transmitted by binding of Fas ligand (FasL) to the Fas receptor (CD95/Apo-1) have pleiotropic effects on cellular function that present opportunities for therapeutic applications. For example, depending on the circumstances, overexpression of FasL can enhance, prevent, or reverse growth of spontaneous or transplantable tumors. Furthermore, local administration of FasL into a single paw in susceptible mice protects from or reduces the severity of collagen-induced arthritis (CIA) in all paws. Here, we define mechanisms that mediate systemic protection induced by locally delivered FasL. Protection is not solely dependent on local interactions between Fas and FasL, but rather requires induction of a paradoxical inflammatory response that not only destroys Fas-resistant tumors, but also recruits motile, activated, Fas-bearing T cells that are Fas sensitive. We demonstrate by following the antigen-specific recruitment and subsequent termination of transgenic T cells that activated T cells, including autoreactive cells responsible for CIA, are eliminated within this inflammatory environment through the overexpressed FasL. The nature of the inflammatory response, which depends on the Fas ligand being cell bound and not soluble, and the magnitude of FasL expression within the inflammatory milieu are essential for this effect, as arthritogenic inflammation alone resulting from CIA induction is insufficient to ameliorate the disease or eliminate antigen-specific T cells, even upon systemic delivery of soluble FasL. These data show that gene delivery of membrane-bound FasL can effectively recruit and eliminate autoreactive T cells 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Research Support, U.S. Gov't, P.H.S. 
650 7 |a Fas Ligand Protein  |2 NLM 
650 7 |a Fasl protein, mouse  |2 NLM 
650 7 |a Membrane Glycoproteins  |2 NLM 
700 1 |a Sun, Juan  |e verfasserin  |4 aut 
700 1 |a Lang, Julie  |e verfasserin  |4 aut 
700 1 |a Vacano, Guido  |e verfasserin  |4 aut 
700 1 |a Patterson, David  |e verfasserin  |4 aut 
700 1 |a Chan, Daniel  |e verfasserin  |4 aut 
700 1 |a Franzusoff, Alex  |e verfasserin  |4 aut 
700 1 |a Gianani, Roberto  |e verfasserin  |4 aut 
700 1 |a Meech, Sandra J  |e verfasserin  |4 aut 
700 1 |a Duke, Richard  |e verfasserin  |4 aut 
700 1 |a Bellgrau, Donald  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 112(2004), 1 vom: 16. Juli, Seite 54-65  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:112  |g year:2004  |g number:1  |g day:16  |g month:07  |g pages:54-65 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 112  |j 2004  |e 1  |b 16  |c 07  |h 54-65